Bernard Reculeau
Keine laufenden Positionen mehr
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Serge Timsit | M | - |
Neurokin SA
 Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | 11 Jahre |
| Jérôme Becquart | M | - |
Neurokin SA
Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | 11 Jahre |
| Yves-Thibault de Silguy | M | 76 |
Ecole Nationale d'Administration
Sciences Po
| 7 Jahre |
| Anne-Marie Idrac | F | 73 |
Ecole Nationale d'Administration
Sciences Po
| 6 Jahre |
| Yves Lyon-Caen | M | 74 |
Ecole Nationale d'Administration
Sciences Po
| 6 Jahre |
| Thierry Marie Varene | M | 72 |
Sciences Po
| 6 Jahre |
| Nonce Paolini | M | 75 |
Sciences Po
| 4 Jahre |
| Bernard David | M | 72 |
Sciences Po
| 6 Jahre |
| Michel Chambaud | M | 72 |
Sciences Po
| 6 Jahre |
| Bénédicte Menn | M | - |
Neurokin SA
Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | 11 Jahre |
| Yehezkel Ben-Ari | M | - |
Neurokin SA
Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | 11 Jahre |
| Michel Kaczorek | M | - |
Neurokin SA
Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | - |
| Beji Tak-Tak | M | - |
Sciences Po
| 4 Jahre |
| Gilles Auffret | M | 77 |
Ecole Nationale d'Administration
| 4 Jahre |
| Louis Jammayrac | M | - |
Neurokin SA
Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | - |
| Marc Tessier | M | 78 |
Sciences Po
| 2 Jahre |
| Bruno Parent | M | 70 |
Ecole Nationale d'Administration
| 4 Jahre |
| Jean-Pierre Paoli | M | 74 |
Ecole Nationale d'Administration
| 4 Jahre |
| Jean-François Griveaud | M | - |
Sciences Po
| 2 Jahre |
| Raphaël Goama Zoungrana | M | - |
Ecole Nationale d'Administration
| 4 Jahre |
| Marc-Olivier Strauss-Kahn | M | 70 |
Sciences Po
| 4 Jahre |
| Olivier Barre | M | 51 |
Sciences Po
| 4 Jahre |
| Henri Giscard d'Estaing | M | 67 |
Sciences Po
| 4 Jahre |
| Patricia Moulin Lemoine | F | 75 |
Sciences Po
| 4 Jahre |
| Jérôme Tixier | M | 70 |
Sciences Po
| 4 Jahre |
| Yannick Chagnon | M | 76 |
Sciences Po
| 4 Jahre |
| Jacques Pélissard | M | 78 |
Sciences Po
| 4 Jahre |
| Daniel Giroux | M | - |
Ecole Nationale d'Administration
| 4 Jahre |
| Francois-Alfred-Mari Pinchon | M | 72 |
Sciences Po
| 4 Jahre |
| Muriel de Szilbereky | F | 72 |
Ecole Nationale d'Administration
| 4 Jahre |
| Michel Dechelotte | M | 68 |
Ecole Nationale d'Administration
| 4 Jahre |
| Priscilla de Moustier | F | 72 |
Sciences Po
| 4 Jahre |
| Philippe Le Jolis de Villiers de Saintignon | M | 75 |
Sciences Po
| 3 Jahre |
| Catherine Pays-Lenique | F | 65 |
Ecole Nationale d'Administration
| 3 Jahre |
| Andrea Workman | F | - |
Sciences Po
| 1 Jahre |
| Christian Schricke | M | 76 |
Ecole Nationale d'Administration
| - |
| Henri de la Croix de Castries | M | 69 |
Ecole Nationale d'Administration
| 4 Jahre |
| Henri de Bodinat | M | - |
Sciences Po
| 2 Jahre |
| Jean-Pierre Renault | M | - |
Sciences Po
| 4 Jahre |
| Baudouin Prot | M | 73 |
Ecole Nationale d'Administration
| 1 Jahre |
| Jean-Pierre Tirouflet | M | - |
Ecole Nationale d'Administration
| 4 Jahre |
| Christian Merle | M | 70 |
Sciences Po
| 4 Jahre |
| Jean-Charles Henri Naouri | M | 75 |
Ecole Nationale d'Administration
| 4 Jahre |
| Thierry Moulonguet | M | 73 |
Ecole Nationale d'Administration
| 4 Jahre |
| Paul Hermelin | M | 72 |
Ecole Nationale d'Administration
| 4 Jahre |
| Michel Cicurel | M | 76 |
Ecole Nationale d'Administration
| 4 Jahre |
| Elie Cohen | M | 74 |
Sciences Po
| 4 Jahre |
| Daniel Camus | M | 70 |
Sciences Po
| 2 Jahre |
| Michael Zaoui | M | 67 |
Sciences Po
| 4 Jahre |
| Régis Saleur | M | 56 |
Neurokin SA
Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | - |
| François Tardan | M | 71 |
Ecole Nationale d'Administration
| 4 Jahre |
| Marc Boudier | M | 74 |
Ecole Nationale d'Administration
| 4 Jahre |
| Anne Le Lorier | F | 71 |
Ecole Nationale d'Administration
| 4 Jahre |
| Bernard Laurent | M | - |
Sciences Po
| 4 Jahre |
| Jean-Marc Espalioux | M | 72 |
Ecole Nationale d'Administration
| 1 Jahre |
| François Auque | M | 68 |
Sciences Po
| 4 Jahre |
| Célia Hart | M | - |
Neurokin SA
Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | - |
| Jean-Marc Janaillac | M | 71 |
Ecole Nationale d'Administration
| 4 Jahre |
| Pierre Mongin | M | 70 |
Ecole Nationale d'Administration
| 4 Jahre |
| Jean-François Cirelli | M | 66 |
Ecole Nationale d'Administration
| 3 Jahre |
| Benoît Claire | M | 75 |
Sciences Po
| 4 Jahre |
| Brigitte Simon | F | 68 |
Sciences Po
| 4 Jahre |
| Abdul Razak bin Ramli | M | 76 |
Ecole Nationale d'Administration
| 4 Jahre |
| Pierre François Mellinger | M | 69 |
Ecole Nationale d'Administration
| 4 Jahre |
| Jacques Kerrest | M | 77 |
Sciences Po
| 1 Jahre |
| Jean-Louis Mattei | M | 76 |
Sciences Po
| 3 Jahre |
| Baruc Leon | M | - |
Sciences Po
| 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Frankreich | 67 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Bernard Reculeau
- Persönliches Netzwerk
